Table 2 Anticoagulation parameters and reversal agents administered
Agents | PCC3 (n = 57) | PCC4 (n = 23) |
|---|---|---|
PCC dose | ||
 Dose (units) | 2000 (1530–2500) | 2595 (1880–3307) |
 Dose by weight (units/kg) | 21.5 (20.4–25.9) | 29.3 (25.9–37.3) |
 Dose by pre-PCC INR (units/INR) | 645.2 (438.3–982.8) | 674.3 (576.5–870.0) |
 Dose by weight/pre-PCC INR (units/kg/INR) | 7.9 (5.6–10.5) | 8.2 (7.0–10.2) |
INR | ||
 INR prior to reversal | 2.8 (2.1–4.1) | 3.7 (2.6–4.9) |
 INR post first dose | 1.7 (1.5–2.0) | 1.3 (1.3–1.4) |
 INR change pre to post | 1.1 (0.6–2.0) | 2.3 (1.2–3.3) |
Time (minutes) | ||
 Minutes from pre-PCC INR to dose given | 78 (56.0–113.0) | 73 (40.0–108.5) |
 Minutes from dose given to post-PCC INR (6 h or less) | 93 (46.0–228.0) | 226 (156.5–368.5) |
 Minutes from pre- to post-PCC INR (12 h or less) | 215 (133.0–326.0) | 296 (241.0–483.0) |
Vitamin K routes, n (%) | ||
 Intravenous | 36 (63.2%) | 21 (91.3%) |
 Oral | 9 (15.8%) | 1 (4.3%) |
 Subcutaneous | 4 (7.0%) | 0 (0.0%) |
 None | 8 (14.0%) | 1 (4.3%) |
Vitamin K given during stay (mg) | 5.0 (2.0–10.0) | 10.0 (7.5–10.0) |
FFP given during stay (yes/no), n (%) | 34 (59.6%) | 7 (30.4%) |
 Units given in those receiving FFP (range) | (1–12) | (1–6) |
FFP given between INR 1 and 2 (yes/no), n (%) | 15 (26.3%) | 2 (8.7%) |
 Units given in those receiving FFP (range) | (1–4) | (1, 2) |
RBC given during stay (yes/no), n (%) | 21 (36.8%) | 7 (30.4%) |
 Units given in those receiving RBC (range) | (1–12) | (1–4) |